Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
基本信息
- 批准号:10459361
- 负责人:
- 金额:$ 59.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirus InfectionsAdenovirusesAffectAmino AcidsAntiviral ResponseBindingBinding SitesBiological AssayBiologyBlack raceCellsCellular StressColorDNA VirusesDataDevelopmentDiseaseDouble-Stranded RNAEnzymesEukaryotic Initiation Factor-2FamilyFamily PicornaviridaeGene ExpressionGoalsGrowthHIV-1Host DefenseHumanIn VitroInfectionInfection ControlKnowledgeLaboratoriesMessenger RNAMissionMolecularMolecular VirologyMurid herpesvirus 1MusNucleic AcidsOrthobunyavirusPathogenesisPhosphorylationPhosphotransferasesProteasome InhibitorProtein AnalysisProtein BiosynthesisRNARNA Polymerase IIIReportingResearchRoleSindbis VirusSystemTestingTimeTranscriptTranslatingTranslationsUbiquitinationUnited States National Institutes of HealthUntranslated RNAViralViral GenesViral PathogenesisViral ProteinsVirusVirus DiseasesVirus Replicationbasecytokinedeprivationdisorder controlexperimental studyhuman diseasein vivoin vivo Modelinnovationmacromoleculemacrophagemortalitymouse modelmulticatalytic endopeptidase complexmutantpreventprotein activationprotein kinase Rresponsevirologyvirus host interaction
项目摘要
Summary
Viruses use many strategies to translate their mRNAs in the face of antiviral responses that would otherwise
block viral protein synthesis. The most prominent antiviral mechanism affecting protein synthesis is
phosphorylation of eukaryotic initation factor 2 (eIF2 by protein kinase R (PKR). Human adenoviruses
(hAds) overcome this via virus-associated (VA) RNAs that block PKR activation. However, mouse adenovirus
type 1 (MAV-1) does not encode VA RNAs; how MAV-1 successfully overcomes PKR is unknown. The role of
another eIF2 kinase, GCN2, in antiviral responses is less well appreciated, but it is antiviral against MAV-1.
There is a critical need to understand how PKR and GCN2 impact viral replication as part of the antiviral
response. The long-term goal is to increase fundamental knowledge about adenovirus-host interactions that
contribute to disease. The overall objective of this application is to determine how MAV-1 modulates host
eIF2 kinases and successfully replicates in the presence of these host antiviral defenses. The central
hypothesis is that MAV-1 overcomes the host antiviral response by reducing PKR levels, whereas MAV-1
activates but does not evade GCN2 in macrophages, target cells of viral replication. This hypothesis is based
on preliminary data that PKR is depleted in MAV-1 infections, GCN2-deficient macrophages produce more
virus, and GCN2-deficient mice are more susceptible and express more proinflammatory cytokines upon
MAV-1 infection than control mice. The rationale is that knowing how MAV-1 induces and counteracts the host
antiviral responses will enable manipulation of these responses and testing their effects in a powerful in vivo
model, which will increase understanding of disease. The specific aims are to determine 1) how MAV-1
counters the host PKR response, and 2) how the host GCN2 response protects mice from MAV-1 infection.
These aims will use assays of MAV-1 pathogenesis and molecular virology established in the applicant's
laboratory. In Aim 1, preliminary data showing that during infection PKR is degraded via the proteasome and
PKR translation is inhibited will be validated and extended to identify the mechanisms and whether specific
viral genes are responsible. Approaches will use viral mutants, PKR-/- mice and cells. Aim 2 will address how
the lack of GCN2 leads to higher mouse mortality and proinflammatory responses, and whether and how
MAV-1 induces GCN2 activation, using viral mutants, and wild type and GCN2-/- mice and cells. The approach
is innovative because it will elucidate for the first time how a DNA virus induces depletion of PKR, and it will
broaden the focus on eIF2 kinase GCN2 as a host antiviral response. The research is significant because it is
expected to have fundamental relevance to virus-host interactions and human disease.
概括
病毒使用许多策略来转化其mRNA,面对抗病毒反应
阻断病毒蛋白合成。影响蛋白质合成的最突出的抗病毒机制是
真核因子因子2的磷酸化(蛋白激酶R(PKR)的EIF2。人腺病毒
(HADS)通过与病毒相关的(VA)RNA(阻断PKR激活)克服了这一点。但是,小鼠腺病毒
类型1(MAV-1)不编码VA RNA; MAV-1如何成功克服PKR是未知的。的作用
在抗病毒反应中的另一种EIF2激酶GCN2不太受欢迎,但它是对MAV-1的抗病毒。
迫切需要了解PKR和GCN2如何影响病毒复制作为抗病毒的一部分
回复。长期目标是增加有关腺病毒宿主相互作用的基本知识
有助于疾病。该应用程序的总体目的是确定MAV-1如何调节主机
EIF2激酶并在存在这些宿主抗病毒防御的情况下成功复制。中央
假设MAV-1通过降低PKR水平克服了宿主抗病毒反应,而MAV-1
激活但不会在巨噬细胞,病毒复制的靶细胞中逃避GCN2。该假设是基于
关于PKR在MAV-1感染中耗尽的初步数据,GCN2缺乏巨噬细胞产生了更多
病毒和GCN2缺乏小鼠更容易敏感,并在上表达更多促炎细胞因子
MAV-1感染比对照小鼠。理由是知道MAV-1如何影响和抵消主机
抗病毒反应将使这些反应能够操纵这些反应并在强大的体内测试其效果
模型,这将增加对疾病的理解。具体目的是确定1)MAV-1如何
计算宿主PKR响应,以及2)宿主GCN2反应如何保护小鼠免受MAV-1感染的影响。
这些目标将使用申请人中建立的MAV-1发病机理和分子病毒学的测定
实验室。在AIM 1中,初步数据表明,在感染期间,PKR通过蛋白酶体和
抑制PKR翻译将得到验证并扩展,以识别机制以及是否具体
病毒基因是负责的。方法将使用病毒突变体,PKR - / - 小鼠和细胞。 AIM 2将解决如何
缺乏GCN2会导致小鼠死亡率和促炎反应,以及是否以及如何以及如何
MAV-1使用病毒突变体以及野生型和GCN2 - / - 小鼠和细胞诱导GCN2激活。方法
具有创新性,因为它将首次阐明DNA病毒如何诱导PKR的耗竭,并且它将
扩大对EIF2激酶GCN2作为宿主抗病毒反应的关注。这项研究很重要,因为它是
预计将与病毒 - 宿主相互作用和人类疾病具有基本相关性。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mouse Adenovirus Type 1 E4orf6 Induces PKR Degradation.
小鼠腺病毒 1 型 E4orf6 诱导 PKR 降解。
- DOI:10.1128/jvi.02063-21
- 发表时间:2022
- 期刊:
- 影响因子:5.4
- 作者:Tejera-Hernández,Berto;Goodman,DanielleE;Nevarez,JuanM;Spindler,KatherineR
- 通讯作者:Spindler,KatherineR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katherine R. Spindler其他文献
Katherine R. Spindler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katherine R. Spindler', 18)}}的其他基金
Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
- 批准号:
9976443 - 财政年份:2018
- 资助金额:
$ 59.51万 - 项目类别:
Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
- 批准号:
9789821 - 财政年份:2018
- 资助金额:
$ 59.51万 - 项目类别:
American Society for Virology Meeting - Jr. Investigator Support Proposal
美国病毒学学会会议 - 初级研究员支持提案
- 批准号:
9932318 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8651867 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
American Society for Virology Meeting- Jr Investigator Support
美国病毒学学会会议 - 初级研究者支持
- 批准号:
10623137 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8183521 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8449166 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8260848 - 财政年份:2011
- 资助金额:
$ 59.51万 - 项目类别:
Cloning a major gene for mouse adenovirus susceptibility
克隆小鼠腺病毒易感性主要基因
- 批准号:
7846601 - 财政年份:2009
- 资助金额:
$ 59.51万 - 项目类别:
Cloning a major gene for mouse adenovirus susceptibility
克隆小鼠腺病毒易感性主要基因
- 批准号:
7753149 - 财政年份:2006
- 资助金额:
$ 59.51万 - 项目类别:
相似国自然基金
CD46和DSG2双受体在人B组腺病毒感染与致病中的协同作用和机制研究
- 批准号:32370155
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
TRIM35调控E1A病毒蛋白抑制腺病毒感染机制的研究
- 批准号:32200124
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
TRIM35调控E1A病毒蛋白抑制腺病毒感染机制的研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
L1-52/55K蛋白定点变异与3型、7型腺病毒感染毒力相关性和机制研究
- 批准号:81701995
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
纤毛杆影响嵌合型腺病毒感染T淋巴细胞效率的机制研究
- 批准号:31400149
- 批准年份:2014
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Pulmonary endothelium targeted adenoviral gene therapy for the correction of mucopolysaccharidosis type I
肺内皮靶向腺病毒基因治疗纠正 I 型粘多糖贮积症
- 批准号:
10678053 - 财政年份:2023
- 资助金额:
$ 59.51万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 59.51万 - 项目类别:
Defining mechanisms of PKR activation and evasion during Adenovirus infection
腺病毒感染期间 PKR 激活和逃避的定义机制
- 批准号:
10535732 - 财政年份:2022
- 资助金额:
$ 59.51万 - 项目类别:
Viral subversion of intercellular coupling during myocarditis
心肌炎期间细胞间耦合的病毒颠覆
- 批准号:
10522824 - 财政年份:2022
- 资助金额:
$ 59.51万 - 项目类别:
Defining mechanisms of PKR activation and evasion during Adenovirus infection
腺病毒感染期间 PKR 激活和逃避的定义机制
- 批准号:
10752610 - 财政年份:2022
- 资助金额:
$ 59.51万 - 项目类别: